5 IPOs Planned for This Week

The following IPOs are expected to price this week: Chesapeake Midstream Partners (CHKM), an L.P. formed by Chesapeake (NYSE:CHK) and GIP to operate natural gas gathering systems, plans to raise $425 million by offering 21.25 million shares at a price range of $19-$21. At the mid-point of the proposed range, Chesapeake Midstream Partners will command a market value of $2.8 billion. Chesapeake booked $383 million in sales over the last 12 months. The Oklahoma City, OK-based company plans to list on the NYSE under the symbol CHKM. UBS Investment Bank (NYSE:UBS), Citi (NYSE:C) and Morgan Stanley (NYSE:MS) are the lead underwriters on the deal.

Envestnet (NYSE:ENV), which provides outsourced web-based investment solutions to financial advisors, plans to raise $100 million by offering 7.7 million shares at a price range of $12-$14. At the mid-point of the proposed range, Envestnet will command a market value of $409 million. Envestnet, which was founded in 1999, booked $78 million in sales over the last 12 months. The Chicago, IL-based company plans to list on the NYSE under the symbol ENV. Morgan Stanley, UBS Investment Bank and Barclays Capital (NYSE:BCS) are the lead underwriters on the deal.

Molycorp (MCP), the only rare earth oxide (REO) producer in the Western Hemisphere, plans to raise $450 million by offering 28.1 million shares at a price range of $15-$17. At the mid-point of the proposed range, Molycorp will command a market value of $1.3 billion. Molycorp, which was founded in 1950, booked $7 million in sales over the last 12 months. The Greenwood Village, CO-based company plans to list on the NYSE under the symbol MCP. J.P. Morgan (NYSE:JPM) and Morgan Stanley (MS) are the lead underwriters on the deal.

SurgiVision (SRGV), which has developed an MRI-guided device for minimally invasive brain procedures, plans to raise $25 million by offering 2.5 million shares at a price range of $13-$15. At the mid-point of the proposed range, SurgiVision will command a market value of $111 million. SurgiVision, which was founded in 1998, booked $3 million in sales over the last 12 months. The Memphis, TN-based company plans to list on the NASDAQ under the symbol SRGV. Canaccord Genuity and Rodman & Renshaw are the lead underwriters on the deal.

Trius Therapeutics (TSRX), which is developing an antibiotic for serious gram-positive Staph infections, plans to raise $78 million by offering 6 million shares at a price range of $12-$14. At the mid-point of the proposed range, Trius Therapeutics will command a market value of $217 million. Trius Therapeutics, which was founded in 2004, booked $5 million in sales over the last 12 months. The San Diego, CA-based company plans to list on the NASDAQ under the symbol TSRX. Citi, Piper Jaffray (NYSE:PJC) and Canaccord Genuity are the lead underwriters on the deal.

Last week, there were 3 IPO pricings. Green Dot (NYSE:GDOT), which is a leading provider of reloadable prepaid debit cards in the US, was the week's winner, ending up 23% from its IPO price.